logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
H

Hong‐Hong Yan

guangdong academy of medical sciences
H指数:40
被引数:7,427
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS)

奥希替尼联合或不联合萨沃利替尼治疗MET异常、EGFR突变非小细胞肺癌的一线治疗：随机II期试验（FLOWERS）

Nature Communications
IF15.7
2026-01-130
OAAI
Anna Li; Wei-Neng Feng; Juan Li; Bing-Fei Xu; Jun Zhao; Yun Jia; Ke-Jing Tang; Yong-Sheng Li; Cheng-Zhi Zhou; Yun Fan; Chong-Rui Xu; Yue-Li Sun; Hua-Jun Chen; Hong-Hong Yan; Zong-Kun Shi; Jin-Ji Yang
Comparing the efficacy and safety of the ABC-14 regimen (azacitidine, venetoclax, and chidamide) with traditional 3+7 intensive induction regimen or AB-14 regimen (venetoclax combined with azacitidine) in newly diagnosed AML: study protocol for a prospective, multicenter, randomized, open-label clinical trial

比较ABC-14方案（azacitidine、venetoclax和chidamide）与传统3+7强化诱导方案或AB-14方案（venetoclax联合azacitidine）在初诊AML中的疗效和安全性：一项前瞻性、多中心、随机、开放标签临床研究的方案

TRIALS
IF2
2025-12-100
PRE
Yan, Honghong; Huang, Xin; Wu, Ping; Deng, Chengxin; Li, Minming; Lai, Peilong; Du, Xin; Weng, Jianyu
PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial

未经治疗的晚期非小细胞肺癌患者sintilimab与pembrolizumab联合或不联合铂类双重化疗的PD-L1表达指南 (CTONG1901): 一项2期随机对照试验

SCIENCE BULLETIN
IF21.1
2024-02-016
OAAI
Liu, Si-Yang Maggie; Huang, Jie; Deng, Jia-Yi; Xu, Chong-Rui; Yan, Hong-Hong; Yang, Ming-Yi; Li, Yang-Si; Ke, E-e; Zheng, Ming-Ying; Wang, Zhen; Lin, Jia-Xin; Gan, Bin; Zhang, Xu-Chao; Chen, Hua-Jun; Wang, Bin-Chao; Tu, Hai-Yan; Yang, Jin-Ji; Zhong, Wen-Zhao; Li, Yangqiu; Zhou, Qing; Wu, Yi-Long
Adjuvant Therapy-Free Strategy for Stage IB to IIIA Non-Small-Cell Lung Cancer Patients After Radical Resection Based on Longitudinal Undetectable Molecular Residual Disease: Prospective, Multicenter, Single-Arm Study (CTONG 2201)
CLINICAL LUNG CANCER
IF3.3
2024-01-016
PRE
Zhang, Jia-Tao; Dong, Song; Gu, Wei-Quan; Zhao, Ning; Liang, Yi; Tang, Wen-Fang; Liu, Shuo-Yan; Wang, Feng; Wang, Guang-Suo; Peng, Bin; Wu, Nan; Yan, Shi; Geng, Guo-Jun; Xie, Ze-Feng; Yang, Yan-Long; Zhang, Jian-Hua; Zhang, Tao; Yang, Nuo; Jiao, Wen-Jie; Xiong, Yuan-Yuan; Cai, Miao; Li, Fang; Chen, Rong-Rong; Yan, Hong-Hong; Liu, Si-Yang Maggie; Yi, Xin; Zhong, Wen-Zhao; Yang, Xue-Ning; Wu, Yi-Long
Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial
ECLINICALMEDICINE
IF10
2023-10-014
OAAI
Liu, Si-Yang Maggie; Dong, Xiao-Rong; Wang, Zhen; Du, Yingying; Cui, Jiu-Wei; Chu, Qian; Xu, Bing-Fei; Zheng, Ming-Ying; Deng, Jia-Yi; Lu, Chang; Wei, Xue-Wu; Li, Yang-Si; Zheng, Mei-Mei; Yang, Ming-Yi; Huang, Jie; Li, Anna; Bai, Xiao-Yan; Sun, Yue-Li; Xu, Chong-Rui; Wang, Bin-Chao; Chen, Hua-Jun; Yang, Jin-Ji; Yan, Hong-Hong; Zhong, Wen-Zhao; Zhou, Qing; Wu, Yi-Long
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial
NATURE MEDICINE
IF50
2023-07-2421
PRE
Liu, Si-Yang Maggie; Tu, Hai-Yan; Wei, Xue-Wu; Yan, Hong-Hong; Dong, Xiao-Rong; Cui, Jiu-Wei; Zhou, Zhen; Xu, Chong-Rui; Zheng, Ming-Ying; Li, Yang-Si; Wang, Zhen; Bai, Xiao-Yan; Li, An-Na; Sun, Yue-Li; Huang, Jie; Lin, Jia-Xin; Ke, E. E.; Xu, Bing-Fei; Lu, Chang; Du, Yingying; Chen, Yuan; Ma, Rui; Wang, Bu-Hai; Cang, Shun-Dong; Wang, Bin-Chao; Chen, Hua-Jun; Yang, Jin-Ji; Li, Yangqiu; Zhou, Qing; Wu, Yi-Long
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial
Signal Transduction and Targeted Therapy
IF52.7
2023-02-240
OAAI
Wen-Zhao Zhong; Hong-Hong Yan; Ke-Neng Chen; Chun Chen; Chun-Dong Gu; Jun Wang; Xue-Ning Yang; Wei-Min Mao; Qun Wang; Gui-Bin Qiao; Ying Cheng; Lin Xu; Chang-Li Wang; Ming-Wei Chen; Xiao-Zheng Kang; Wan-Pu Yan; Ri-Qiang Liao; Jin-Ji Yang; Xu-Chao Zhang; Si-Yang Liu; Qing Zhou; Yi-Long Wu
Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non-Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705)
CLINICAL LUNG CANCER
IF3.3
2022-11-015
PRE
Liu, Si-Yang Maggie; Yan, Hong-Hong; Wei, Xue-Wu; Lu, Chang; Dong, Xiao-Rong; Du, Yingying; Cui, Jiu-Wei; Chen, Yuan; Ma, Rui; Wang, Bu-Hai; Zhou, Zhen; Cang, Shun-Dong; Yang, Jin-Ji; Tu, Hai-Yan; Zhang, Xu-Chao; Zhong, Wen-Zhao; Zhou, Qing; Wu, Yi-Long
Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer
CANCER DISCOVERY
IF33.3
2022-05-11118
OAAI
Zhang, Jia-Tao; Liu, Si-Yang; Gao, Wei; Maggie, Si-Yang; Yan, Hong -Hong; Ji, Liyan; Chen, Yu; Gong, Yuhua; Lu, Hong-Lian; Lin, Jun-Tao; Yin, Kai; Jiang, Ben -Yuan; Nie, Qiang; Liao, Ri-Qiang; Dong, Song; Guan, Yanfang; Dai, Pingping; Zhang, Xu-Chao; Yang, Jin-Ji; Tu, Hai-Yan; Xia, Xuefeng; Yi, Xin; Zhou, Qing; Zhong, Wen-Zhao; Yang, Xue-Ning; Wu, Yi-Long
Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study

中国肺腺癌患者完全切除术后基于EGFR突变状态的真实世界生存结果: ICAN研究的结果

JTO CLINICAL AND RESEARCH REPORTS
IF3.5
2022-01-0127
OA
Yang, Xue-Ning; Yan, Hong-Hong; Wang, Jun; Chu, Xiang-Yang; Liu, Zhi-Dong; Shen, Yi; Ma, Hai-Tao; Fu, Xiang-Ning; Hu, Jian; Zhou, Nai-Kang; Liu, Yong-Yu; Zhou, Xin-Ming; Li, Jing-Song; Yang, Kang; Li, Jian; Xu, Lin; Wang, Si-Yu; Wang, Qun; Liu, Lun-Xu; Xu, Shun; Chen, Zhong-Yuan; Lou, Hong-He; Wang, Chang-Li; Cheng, Ying; Liu, Si-Yang; Zhang, Xu-Chao; Zhong, Wen-Zhao; Wu, Yi-Long
Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes

基因组特征定义了EGFR突变II-III期非小细胞肺癌的三种亚型，具有不同的辅助治疗结果

NATURE COMMUNICATIONS
IF15.7
2021-11-0855
OAAI
Liu, Si-Yang; Bao, Hua; Wang, Qun; Mao, Wei-Min; Chen, Yedan; Tong, Xiaoling; Xu, Song-Tao; Wu, Lin; Wei, Yu-Cheng; Liu, Yong-Yu; Chen, Chun; Cheng, Ying; Yin, Rong; Yang, Fan; Ren, Sheng-Xiang; Li, Xiao-Fei; Li, Jian; Huang, Cheng; Liu, Zhi-Dong; Xu, Shun; Chen, Ke-Neng; Xu, Shi-Dong; Liu, Lun-Xu; Yu, Ping; Wang, Bu-Hai; Ma, Hai-Tao; Yan, Hong-Hong; Dong, Song; Zhang, Xu-Chao; Su, Jian; Yang, Jin-Ji; Yang, Xue-Ning; Zhou, Qing; Wu, Xue; Shao, Yang; Zhong, Wen-Zhao; Wu, Yi-Long

研究方向

暂未获取到该数据
Y
Yi‐Long Wu
H 指数:135论文数:2,242被引数:11.1万
J
Jin‐Ji Yang
H 指数:50论文数:296被引数:8,847
钟
钟文昭
H 指数:58论文数:527被引数:1.2万
周
周清
H 指数:58论文数:532被引数:1.6万
X
Xu‐Chao Zhang
H 指数:49论文数:299被引数:9,024
H
Hai‐Yan Tu
H 指数:36论文数:292被引数:6,441
C
Chong‐Rui Xu
H 指数:36论文数:284被引数:7,268
苏剑 封面图
苏剑
H 指数:48论文数:277被引数:8,091
H
Hua‐Jun Chen
H 指数:33论文数:204被引数:4,613
X
Xue‐Ning Yang
H 指数:36论文数:286被引数:6,621